-
Merck reports phase 3 KEYNOTE─B96 trial meets secondary endpoint of OS in all comers population of patients with platinum─resistant recurrent ovarian cancer
18 Oct 2025 07:55 GMT
… in all comers. The trial studied Keytruda (pembrolizumab), … treat ovarian cancer. Lynparza (olaparib), which is being jointly … Food and Drug Administration (FDA) for the treatment of adult … efforts include trials focused on evaluating its medicines in earlier …
-
<![CDATA[Dr Elias on the Role of Olaparib Maintenance Therapy For BRCA1/2-Mutated Ovarian Cancer]]>
17 Oct 2025 17:33 GMT
… 3 SOLO-1 trial (NCT01844986), which solidified olaparib’s role in … highlighted that maintenance olaparib substantially alters the treatment trajectory for patients … with BRCA-mutated disease. Across trials, olaparib …
-
<![CDATA[Treatment Sequencing and Patient Adherence With CDK4/6 Inhibitors]]>
16 Oct 2025 20:44 GMT
… . For BRCA-positive patients, olaparib therapy is typically completed first … 6 inhibitor addition once medication access is secured. Treatment sequencing also incorporates … progression, utilizing available clinical trial data to guide decision-making …
-
AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO
14 Oct 2025 10:05 GMT
… trial of Datroway (datopotamab deruxtecan) as 1st-line treatment … four major pivotal trials at this year’ … and commercialise Lynparza (olaparib), and collaborating with Hutchmed … and commercialisation of prescription medicines in oncology, rare diseases …
-
<![CDATA[Olaparib Withstands the Test of Time With Long-Term Data Supporting Its Role in Ovarian Cancer Treatment]]>
13 Oct 2025 22:46 GMT
… SOLO-2 (NCT01874353) trials collectively established olaparib (Lynparza) as a … persist regarding olaparib use in ovarian cancer treatment?
We still … AEs].
We know these medicines have a risk of … a phase III trial assessing maintenance olaparib in patients (pts …
-
<![CDATA[Dr Elias on Efficacy Data With Olaparib in BRCA-Mutated Ovarian Cancer]]>
10 Oct 2025 22:39 GMT
… or until disease progression. The trial’s primary end point was … not received subsequent treatment. In total, 42.1% of olaparib patients vs … that both SOLO trials provided consistent evidence supporting olaparib as an effective …
-
<![CDATA[Dr Van Tine on Investigating Olaparib Plus Temozolomide vs Investigator’s Choice of Therapy in Advanced Uterine Leiomyosarcoma]]>
07 Oct 2025 00:48 GMT
… the Washington University School of Medicine, outlined the scientific rationale … /3 Alliance A092104 trial (NCT05432791) investigating olaparib (Lynparza) plus temozolomide … improved outcomes compared with standard treatment, with efficacy and biomarker …
-
<![CDATA[Understanding Your Stage 2 Ovarian Cancer]]>
21 Oct 2025 22:55 GMT
… and Pelvic Exam: Your doctor will feel for masses … Targeted Therapy and Maintenance Treatment
Targeted Therapy: Drugs that focus on specific … Inhibitors (e.g., Lynparza (olaparib)) are a common type used … and honest with your medical team about your symptoms …
-
Enhertu demonstrated highly statistically significant and clinically meaningful improvement in IDFS vs. T─DM1 in DESTINY─Breast05 phase III trial in patients with high─risk early breast cancer following neoadjuvant therapy
30 Sep 2025 05:35 GMT
… DESTINY-Breast05 phase III trial showed Enhertu (trastuzumab … HER2-directed DXd antibody drug conjugate (ADC) discovered … 47;or DESTINY-Gastric06 trials. Continued approval in … medicine camizestrant.
PARP inhibitor Lynparza (olaparib) is a targeted treatment …
-
Enhertu plus pertuzumab granted Priority Review in US as 1st-line treatment for patients with HER2-positive metastatic breast cancer
25 Sep 2025 03:31 GMT
… Drug Administration (FDA) grants Priority Review to applications for medicines … “The DESTINY-Breast09 trial showed that treating … or DESTINY-Lung05 trials. Continued approval in … medicine camizestrant.
PARP inhibitor Lynparza (olaparib) is a targeted treatment …
About
© 1995-2025